Katayama S
Fourth Department of Medicine, Saitama Medical School.
Nihon Rinsho. 1997 Aug;55(8):2091-6.
The number of patients with non-insulin-dependent-diabetes mellitus (NIDDM) is dramatically increasing in Japan and estimated to be 6 million, more than one of ten adults. It is well known that more than a half of diabetics are hypertensive. Therefore, it is very important to treat hypertension to reduce cardiovascular events as well as end-stage renal disease. At first, life style modification such as body weight reduction, exercise and restriction of salt and alcohol intake will be recommended. Improved glycemic control by such a non-pharmacological therapy will lower blood pressure. Recent studies demonstrated that hypoglycemic agents improving insulin resistance such as metformin and troglitazone reduce blood pressure. If these maneuvers do not lower blood pressure, hypotensive medication will be necessary. As a first line therapy, ACE inhibitor, alpha 1-blocker or Ca-channel blocker will be selected. In diabetics with proteinuria or micro-albuminuria, ACE inhibitors will be effective to delay the progression of diabetic nephropathy.
在日本,非胰岛素依赖型糖尿病(NIDDM)患者数量急剧增加,估计达600万,超过十分之一的成年人。众所周知,超过一半的糖尿病患者患有高血压。因此,治疗高血压对于减少心血管事件以及终末期肾病非常重要。首先,建议进行生活方式的改变,如减轻体重、运动以及限制盐和酒精的摄入。通过这种非药物疗法改善血糖控制将降低血压。最近的研究表明,二甲双胍和曲格列酮等改善胰岛素抵抗的降糖药物可降低血压。如果这些措施不能降低血压,则需要使用降压药物。作为一线治疗,将选择ACE抑制剂、α1受体阻滞剂或钙通道阻滞剂。对于有蛋白尿或微量白蛋白尿的糖尿病患者,ACE抑制剂将有效延缓糖尿病肾病的进展。